You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Author's response to letter on number needed to treat in COPD: exacerbations versus pneumonias

https://doi.org/10.1136/thoraxjnl-2013-203461

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests The author has received research grants and/or participated in advisory meetings or as conference speaker for AstraZeneca, Boehringer-Ingelheim, Forest, GlaxoSmithKline, Merck, Novartis, Nycomed and Pfizer.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles